MCC950 – 1 mg

Brand:
Cayman
CAS:
210826-40-7
Storage:
-20
UN-No:
Non-Hazardous - /

NOD-like receptor (NLR) pyrin domain-containing protein 3 (NLRP3) senses pathogen-derived, environmental, and host-derived factors and initiates the formation of inflammasomes, complexes involved in complex diseases including multiple sclerosis, type 2 diabetes, Alzheimer’s disease, and atherosclerosis.{28326} MCC950 is a selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM).{28329} It does not inhibit NLRC4, AIM2, TLR2 signaling, or priming of NLRP3. MCC950 prevents oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) in cells stimulated with LPS and nigericin.{28329} MCC-950 is active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome.{28329} It is also active in ex vivo samples from individuals with Muckle-Wells syndrome.  

 

Available on backorder

SKU: - Category:

Description

A selective inhibitor of NLRP3, blocking the release of IL-1β in macrophages primed with LPS and activated with ATP or nigericin (IC50 = 7.5 nM); active in vivo, blocking the production of IL-1β and enhancing survival in mouse models of multiple sclerosis and cryopyrin-associated periodic syndrome


Formal name: N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide

Synonyms:  CP 456,773

Molecular weight: 404.5

CAS: 210826-40-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease